Freenome Inc. Common stock (FRNM)

About FRNM

Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung,…

Sector

Health Care

Industry

Medical Specialities

Employees

375

Fundamentals

1-day range

$13.81$15.09

Market cap

$1.18B

P/E (trailing)

—

P/E (forward)

-6.16

EPS (trailing)

$-0.07

Dividend yield

—

Beta

0.05

Avg. volume

483.4K

Freenome Inc. Common stock Competitors

Chosen by industry and closest market cap.

• FRNM

  Freenome Inc. Common stock

  $14.77

  ▲ 5.95%
  Market cap $1.18BP/E —
  $9.97$14.34
• TRUP

  Trupanion Inc. Common Stock

  $29.64

  ▼ 0.03%
  Market cap $1.09BP/E 57.51
  $21.16$46.98
• LMRI

  Lumexa Imaging Holdings Inc. Common Stock

  $11.5

  ▼ 1.96%
  Market cap $1.08BP/E —
  $6.45$19.45
• CSTL

  Castle Biosciences Inc. Common Stock

  $33.57

  ▼ 2.03%
  Market cap $928.40MP/E —
  $17.72$44.28
• FTRE

  Fortrea Holdings Inc. Common Stock

  $18.81

  ▼ 0.27%
  Market cap $1.80BP/E —
  $8.31$21.39
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $1.99BP/E —
  $13.18$34.29
• TLSI

  TriSalus Life Sciences Inc. Common Stock

  $4.85

  ▼ 1.62%
  Market cap $291.73MP/E —
  $2.2$7.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
  Benzinga · 8/28/2026
• Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
  benzinga · 8/20/2026
• Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
  Benzinga · 8/20/2026
• Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
  Benzinga · 8/18/2026
• TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
  Benzinga · 8/18/2026
• Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
  Benzinga · 8/17/2026
• BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
  Benzinga · 8/17/2026
• Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
  Benzinga · 8/14/2026
• Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung
  Benzinga · 8/12/2026

• Harlan Waksal · July 20, 2026 · Conversion

  30.0K
• Kenneth Song · July 20, 2026 · Conversion

  30.0K
• Perceptive Capital Solutions Holdings · July 20, 2026 · Conversion

  2.07M
• Mark C. McKenna · July 20, 2026 · Conversion

  30.0K
• Michael Seth Altman · July 20, 2026 · Conversion

  2.07M
• Adam Leo Stone · July 20, 2026 · Conversion

  2.07M
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  337.0K @ $10
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  4.92M @ $10
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  367.4K
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  908.1K
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  553.7K
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  971.0K
• RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Grant

  6.56M
• PERCEPTIVE ADVISORS LLC · July 20, 2026 · Grant

  5.50M @ $10